Iovance To Press Ahead With Melanoma Cell Therapy Filing Despite Doubters

Still Expects To File In 2022

 
• By Andrew McConaghie
  
Iovance
Iovance is no stranger to share price turbulence, but looks well placed to file its potential first-in-class cell therapy in August. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip